Identifying molecular features for prostate cancer with Gleason 7 based on microarray gene expression profiles

Romanian Journal of Morphology and Embryology

Volumn 52, Issue 4, 2011, Pages 1195-1202

  Bǎlǎcescu, Loredana ^a,b   Balacescu O ^a   Crisan N ^c   Fetica, B ^d   Petrut B ^a   Bungǎrdean, Cǎtǎlina ^e   Rus, Meda ^a,b   Tudoran, Oana ^a,e   Meurice, G ^f   Irimie, Al ^a,e   Dragos N ^b   Berindan Neagoe, Ioana ^a,e  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b BABE BOLYAI UNIVERSITY   (Romania)

^c Clinical Municipal Hospital   (Romania)

^d Department of Pathology ^*  (Romania)

^e IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Gene expression; Microarray; Prostate cancer

Indexed keywords

AGED; ARTICLE; CANCER GRADING; CLUSTER ANALYSIS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY;

AGED; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS;

EID: 84855456203     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siegel R, Ward E, Brawley O, Jemal A, Cancer statistics, 2011, CA Cancer J Clin, 2011, 61(4):212-236.
2. Rao AR, Motiwala HG, Karim OM, The discovery of prostate-specific antigen, BJU Int, 2008, 101(1):5-10.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, 2009, 360(13):1320-1328.
4. van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH, Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit, Eur J Cancer, 2010, 46(2):377-383.
5. Sørensen KD, Ørntoft TF, Discovery of prostate cancer biomarkers by microarray gene expression profiling, Expert Rev Mol Diagn, 2010, 10(1):49-64.
6. Smyth GK, Limma: linear models for microarray data. In: Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S (eds), Bioinformatics and computational biology solutions using R and bioconductor (Statistics for Biology and Health), Springer, New York, 2005, 397-420.
7. Madu CO, Lu Y, Novel diagnostic biomarkers for prostate cancer, J Cancer, 2010, 1:150-177.
8. Quinn DI, Henshall SM, Sutherland RL, Molecular markers of prostate cancer outcome, Eur J Cancer, 2005, 41(6):858-887.
9. Elmore LW, Forsythe R, Forsythe H, Bright AT, Nasim S, Endo K, Holt SE, Overexpression of telomerase-associated chaperone proteins in prostatic intraepithelial neoplasia and carcinomas, Oncol Rep, 2008, 20(3):613-617.
10. Valenti MT, Dalle Carbonare L, Bertoldo F, Donatelli L, Lo Cascio V, The effects on hTERT gene expression is an additional mechanism of amino-bisphosphonates in prostatic cancer cells, Eur J Pharmacol, 2008, 580(1-2):36-42.
11. Stark JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein AS, Ma J, Fiorentino M, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA, Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol, 2009, 27(21):3459-3464.
12. Pflug BR, Reiter RE, Nelson JB, Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines, Prostate, 1999, 40(4):269-273.
13. Yang G, Truong LD, Wheeler TM, Thompson TC, Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker, Cancer Res, 1999, 59(22):5719-5723.
14. Zunich SM, Douglas T, Valdovinos M, Chang T, Bushman W, Walterhouse D, Iannaccone P, Lamm ML, Paracrine sonic hedgehog signalling by prostate cancer cells induces osteoblast differentiation, Mol Cancer, 2009, 8:12.
15. Wlazlinski A, Engers R, Hoffmann MJ, Hader C, Jung V, Müller M, Schulz WA, Downregulation of several fibulin genes in prostate cancer, Prostate, 2007, 67(16):1770-1780.
16. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, Scardino PT, Rosen N, Sawyers CL, Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer, Cancer Cell, 2011, 19(5):575-586.
17. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB, Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma, Cancer Res, 2001, 61(24):8617-8623.
18. Kim BH, Kim CI, Chang HS, Choe MS, Jung HR, Kim DY, Park CH, Cyclooxygenase-2 overexpression in chronic inflammation associated with benign prostatic hyperplasia: is it related to apoptosis and angiogenesis of prostate cancer? Korean J Urol, 2011, 52(4):253-259.
19. Golovko O, Nazarova N, Tuohimaa P, A20 gene expression is regulated by TNF, Vitamin D and androgen in prostate cancer cells, J Steroid Biochem Mol Biol, 2005, 94(1-3):197-202.
20. Verstrepen L, Carpentier I, Verhelst K, Beyaert R, ABINs: A20 binding inhibitors of NF-kappa B and apoptosis signaling, Biochem Pharmacol, 2009, 78(2):105-114.
21. Liao Z, Nevalainen MT, Targeting transcription factor Stat5a/b as a therapeutic strategy for prostate cancer, Am J Transl Res, 2011, 3(2):133-138.
22. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT, Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade, Cancer Res, 2004, 64(14): 4774-4782.
23. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT, Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence, Clin Cancer Res, 2005, 11(16):5863-5868.
24. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, Nevalainen MT, Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo, Endocr Relat Cancer, 2010, 17(2):481-493.
25. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M, Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer, J Natl Cancer Inst, 2009, 101(7):519-532.
26. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K, van de Rijn M, Brooks JD, Pollack JR, A trimarker proliferation index predicts biochemical recurrence after surgery for prostate cancer, PLoS One, 2011, 6(5): e20293.
27. Jenal M, Britschgi C, Fey MF, Tschan MP, Inactivation of the hypermethylated in cancer 1 tumour suppressor - not just a question of promoter hypermethylation? Swiss Med Wkly, 2010, 140:w13106.
28. Greer EL, Brunet A, FOXO transcription factors at the interface between longevity and tumor suppression, Oncogene, 2005, 24(50):7410-7425.
29. Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W, FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment, Mol Endocrinol, 2009, 23(2):213-225.
30. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP, Vadgama JV, Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells, Mol Cancer Ther, 2010, 9(1):33-45.